1.31

1.50% -0.02

Allarity Therapeutics Inc (ALLR)

Overview News Price History Financials Discussions Forecast Stock Split

Allarity Therapeutics Inc stock is traded at $1.31, with a volume of 116.47K. It is down -1.50% in the last 24 hours and down -22.49% over the past month. Allarity Therapeutics Inc is a clinical-stage, precision medicine pharmaceutical company focused on developing novel anti-cancer therapeutics for patients with high unmet medical needs. The company is actively advancing the development of stenoparib, an orally available, small-molecule inhibitor for patients with advanced recurrent ovarian cancer. It is leveraging its proprietary Drug Response Predictor (DRP) technology to refine patient selection and improve clinical outcomes. The company operates as a single operating and reporting segment (developing a treatment for ovarian cancer) in two geographic areas: Denmark and the United States. It is focused on the clinical development of its lead program: Stenoparib, which is being co-developed with a drug specific DRP companion diagnostic.

Previous Close:

$1.33

Open:

$1.3

24h Volume:

116.47K

Relative Volume:

0.62

Market Cap:

$20.84M

Revenue:

$345.00K

Net Income/Loss:

$-11.25M

P/E Ratio:

-1.8152

EPS:

-0.7217

Net Cash Flow:

$-16.70M

1W Performance:

+3.15%

1M Performance:

-22.49%

6M Performance:

+14.91%

1Y Performance:

+31.00%

1-Day Range:

$1.28

$1.40

1-Week Range:

$1.26

$1.40

52-Week Range:

$0.7687

$2.35

Allarity Therapeutics Inc Stock (ALLR) Company Profile

Name

Allarity Therapeutics Inc

Sector

Healthcare (1098)

Industry

Biotechnology (615)

Phone

401-426-4664

Address

24 SCHOOL ST., 2ND FLOOR, BOSTON

Employee

Twitter

Next Earnings Date

2026-08-21

Latest SEC Filings

ALLR's Discussions on Twitter

Compare ALLR vs VRTX, REGN, ARGX, ALNY, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
ALLR Allarity Therapeutics Inc	1.31	20.52M	345.00K	-11.25M	-16.70M	-0.7217
VRTX Vertex Pharmaceuticals Inc	528.04	126.07B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	654.27	65.37B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	939.68	57.70B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	312.78	40.19B	4.29B	577.22M	641.34M	4.2086
RVMD Revolution Medicines Inc	189.24	39.82B	742.00K	-1.37B	-1.07B	-7.0731

Allarity Therapeutics Inc Stock (ALLR) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jul-28-25	Initiated	Ascendiant Capital Markets	Buy

Allarity Therapeutics Inc Stock (ALLR) Latest News

Jul 01, 2026

Enterprise value to EBITDA forward of Allarity Therapeutics, Inc. – NASDAQ:ALLR - TradingView

Jul 01, 2026

Tranche Update on Allarity Therapeutics, Inc.'s Equity Buyback Plan announced on March 3, 2025. - marketscreener.com

Jul 01, 2026

Allarity Wins Key U.S. Patent for Stenoparib Diagnostic - TipRanks

Jul 01, 2026

Allarity Therapeutics (NASDAQ: ALLR) wins key DRP patent and secures shareholder backing - Stock Titan

Jul 01, 2026

Jun 30, 2026

Enterprise value to revenue forward of Allarity Therapeutics, Inc. – NASDAQ:ALLR - TradingView

Jun 30, 2026

Allarity receives U.S. patent for stenoparib diagnostic test - Investing.com

Jun 30, 2026

Allarity Therapeutics Announces the Grant of Essential U.S. Patent for Its Stenoparib DRP® Companion Diagnostic - GlobeNewswire

Jun 30, 2026

Price to earnings forward of Allarity Therapeutics, Inc. – NASDAQ:ALLR - TradingView

Jun 30, 2026

Price to book forward of Allarity Therapeutics, Inc. – NASDAQ:ALLR - TradingView

Jun 30, 2026

Jun 26, 2026

Allarity Therapeutics, Inc. Actuals & Estimates (NASDAQ:ALLR) - TradingView

Jun 26, 2026

ALLR Forecast — Price Target — Prediction for 2027 - TradingView

Jun 26, 2026

Jun 24, 2026

Is Allarity Therapeutics, Inc. (ALLR) outperforming other medical stocks this year? - MSN

Jun 24, 2026

Jun 23, 2026